OverviewSuggest Edit

MannKind Corporation focuses on the discovery, development, and commercialization of therapeutic products for patients with diseases such as diabetes. The Company's lead product candidate, Afrezza, is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. Afrezza is a rapid-acting inhaled insulin therapy indicated to improve glycemic control in adults with diabetes. Taken at the start of a meal using a specially designed inhaler, Afrezza dissolves rapidly upon inhalation to the deep lung and delivers insulin quickly to the bloodstream.

TypePublic
Founded1991
HQWestlake Village, US
Websitemannkindcorp.com
Employee Ratings3.2
Overall CultureA+

Latest Updates

Employees (est.) (Dec 2019)232(+4%)
Job Openings8
Revenue (FY, 2019)$63 M(+127%)
Share Price (Nov 2020)$2.8 (-1%)
Cybersecurity ratingAMore

Key People/Management at MannKind Corporation

Michael Castagna

Michael Castagna

Chief Executive Officer, Director
Ronald Consiglio

Ronald Consiglio

Director
Kent Kresa

Kent Kresa

Chairman of the Board
Henry L. Nordhoff

Henry L. Nordhoff

Director
Patrick McCauley

Patrick McCauley

Chief Commercial Officer
David M. Kendall

David M. Kendall

Chief Medical Officer
Show more

MannKind Corporation Office Locations

MannKind Corporation has offices in Westlake Village and Danbury
Westlake Village, US (HQ)
30930 Russell Ranch Rd #301
Danbury, US
1 Casper St
Show all (2)

MannKind Corporation Financials and Metrics

MannKind Corporation Revenue

Embed Graph
View revenue for all periods
MannKind Corporation's revenue was reported to be $63.04 m in FY, 2019 which is a 126.3% increase from the previous period.
USD

Revenue (Q3, 2020)

15.4m

Gross profit (Q3, 2020)

11.8m

Gross profit margin (Q3, 2020), %

76.6%

Net income (Q3, 2020)

(11.3m)

EBIT (Q3, 2020)

(9.1m)

Market capitalization (18-Nov-2020)

646.6m

Closing stock price (18-Nov-2020)

2.8

Cash (30-Sept-2020)

52.4m

EV

646.1m
MannKind Corporation's current market capitalization is $646.6 m.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

11.7m27.9m63.0m

Revenue growth, %

(93%)137%126%

Cost of goods sold

17.2m19.4m20.1m

Gross profit

(5.5m)8.5m43.0m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

3.5m3.9m4.5m17.4m15.0m14.6m16.2m15.1m15.4m

Cost of goods sold

4.0m5.1m5.3m4.0m4.3m7.1m4.2m3.7m3.6m

Gross profit

(543.0k)(1.2m)(834.0k)13.4m10.7m7.5m12.1m11.4m11.8m

Gross profit Margin, %

(16%)(31%)(19%)77%71%51%74%76%77%
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

43.9m71.2m29.9m

Accounts Receivable

2.8m4.0m3.5m

Prepaid Expenses

3.0m2.6m2.9m

Inventories

2.7m3.6m4.2m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

26.7m26.2m10.4m34.5m8.0m30.2m38.9m63.2m52.4m

Accounts Receivable

1.6m2.8m2.8m3.8m5.0m4.1m5.0m3.4m4.1m

Prepaid Expenses

2.4m2.6m3.0m2.4m2.7m3.6m1.9m1.9m4.6m

Inventories

3.9m3.7m2.8m3.7m4.0m3.7m3.2m3.8m4.9m
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(117.3m)(87.0m)(51.9m)

Depreciation and Amortization

3.5m2.9m972.0k

Inventories

(3.3m)(3.2m)(558.0k)

Accounts Payable

3.8m(1.6m)(593.0k)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(30.4m)(53.1m)(77.2m)(14.9m)(27.3m)(37.6m)(9.3m)(19.6m)(30.8m)

Depreciation and Amortization

706.0k1.5m2.5m367.0k739.0k407.0k538.0k1.1m1.6m

Inventories

(1.8m)(1.8m)(1.9m)(123.0k)(366.0k)(95.0k)428.0k(164.0k)(1.2m)

Accounts Payable

(2.0m)2.3m(1.2m)1.6m2.2m6.3m1.9m1.0m1.0m
USDFY, 2017

EV/EBIT

-2.9 x

EV/CFO

-4.8 x

Revenue/Employee

47.0k

Debt/Equity

-0.4 x

Debt/Assets

0.9 x

Financial Leverage

-0.4 x

P/E Ratio

(2.1)
Show all financial metrics

MannKind Corporation Operating Metrics

FY, 2017FY, 2018FY, 2019

Patents Issued

930 1.02 k

Patents Issued (Afrezza)

530 570 600

Patent Applications

280 240

Patent Applications (Afrezza)

200 160 125
Show all operating metrics

MannKind Corporation Revenue Breakdown

Embed Graph

MannKind Corporation revenue breakdown by business segment: 40.1% from Commercial Product Sales and 59.9% from Collaboration

MannKind Corporation Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

MannKind Corporation Online and Social Media Presence

Embed Graph

MannKind Corporation Company Culture

  • Overall Culture

    A+

    92/100

  • CEO Rating

    A+

    96/100

  • Compensation

    A+

    92/100

Learn more on Comparably

MannKind Corporation News and Updates

MannKind Corporation Reports 2020 Third Quarter Financial Results

Conference Call to Begin Today at 5:00 PM ET

MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results

Conference Call to Begin Today at 9:00 AM ET Conference Call to Begin Today at 9:00 AM ET

MannKind Corporation Reports 2019 Third Quarter Preliminary Financial Results

Conference Call to Begin Today at 9:00 AM ET Conference Call to Begin Today at 9:00 AM ET

MannKind Corporation to Present at H.C. Wainwright 21st Annual Global Investment Conference

WESTLAKE VILLAGE, Calif., Aug. 30, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will …

MannKind Corporation to Hold 2019 Second Quarter Financial Results Conference Call on August 7, 2019

WESTLAKE VILLAGE, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) will release its 2019 second quarter and year-to-date financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on…

MannKind Corporation Reports 2019 First Quarter Financial Results

Conference Call to Begin Today at 9:00 AM ET Conference Call to Begin Today at 9:00 AM ET
Show more

MannKind Corporation Blogs

MannKind Corporation to Hold 2020 Third Quarter Financial Results Conference Call on November 4, 2020

MannKind Corporation to Hold 2020 Third Quarter Financial Results Conference Call on November 4, 2020 Content Import Thu, 10/29/2020 - 08:03 MannKind Corporation to Hold 2020 Third Quarter Financial Results Conference Call on November 4, 2020 10/29/20 This rel…

Kevin Kaiserman Joins MannKind as Vice President, Medical Affairs and Safety

Kevin Kaiserman Joins MannKind as Vice President, Medical Affairs and Safety ronryan.teano@… Mon, 08/31/2020 - 09:01 Kevin Kaiserman Joins MannKind as Vice President, Medical Affairs and Safety 08/31/20 This release is a backfill from a News …

MannKind Corporation Reports 2020 Second Quarter Financial Results

Conference Call to Begin Today at 5:00 PM ET 2Q 2020 Afrezza Net Revenue of $7.0 million ; +15% vs. 2Q 2019 1H 2020 Afrezza Net Revenue of $15.0 million ; +35% vs. 1H 2019 Cash and cash equivalents of $63.2 million at June 30, 2020 Non-GAAP cash used in operating activities decreased by 37% vs.

MannKind Corporation to Hold 2020 Second Quarter Financial Results Conference Call on August 5, 2020

WESTLAKE VILLAGE, Calif. , July 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 second quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, August

Alejandro Galindo Joins MannKind as Chief Commercial Officer

WESTLAKE VILLAGE, Calif. , July 20, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that effective August 4, 2020 , Alejandro Galindo , M.B.A, M.S., will be leading MannKind’s commercial operations as Chief Commercial Officer. Mr.

MannKind Presents Positive Original Analyses of Afrezza® Clinical Data at  American Diabetes Association (ADA) 80th Scientific Sessions

WESTLAKE VILLAGE, Calif. , June 15, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that new data from clinical studies of Afrezza® (insulin human) Inhalation Powder was presented at the American Diabetes Association’s 80th Scientific Sessions , June 12-16, 2020 .
Show more

MannKind Corporation Frequently Asked Questions

  • When was MannKind Corporation founded?

    MannKind Corporation was founded in 1991.

  • Who are MannKind Corporation key executives?

    MannKind Corporation's key executives are Michael Castagna, Ronald Consiglio and Kent Kresa.

  • How many employees does MannKind Corporation have?

    MannKind Corporation has 232 employees.

  • What is MannKind Corporation revenue?

    Latest MannKind Corporation annual revenue is $63 m.

  • What is MannKind Corporation revenue per employee?

    Latest MannKind Corporation revenue per employee is $271.7 k.

  • Who are MannKind Corporation competitors?

    Competitors of MannKind Corporation include Amgen, Assertio Therapeutics and Lexicon Pharmaceuticals.

  • Where is MannKind Corporation headquarters?

    MannKind Corporation headquarters is located at 30930 Russell Ranch Rd #301, Westlake Village.

  • Where are MannKind Corporation offices?

    MannKind Corporation has offices in Westlake Village and Danbury.

  • How many offices does MannKind Corporation have?

    MannKind Corporation has 2 offices.